Gamitrinib TPP is a mitochondrial targeted HSP90 inhibitor exhibiting potent anti-cancer activity. Additionally, Gamitrinib TPP functions as a mitochondrial matrix inhibitor by targeting Gamitrinib (GA).
AMP-PCP is an ATP analog and can bind to the Hsp90 N-terminal domain (Kd: 3.8 μM). AMP-PCP binding favors the formation of the active homodimer of Hsp90.